BioRestorative Therapies, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
BRTX Nasdaq 3850 www.biorestorative.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioRestorative Therapies, Inc.

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform - Apr 30th, 2026 8:36 am
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing - Apr 27th, 2026 7:55 am
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform - Apr 21st, 2026 6:00 am
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform - Apr 7th, 2026 6:15 am
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease - Mar 30th, 2026 6:00 am
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates - Mar 26th, 2026 4:25 pm
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Mar 24th, 2026 3:25 pm
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates - Mar 19th, 2026 3:30 pm
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease - Mar 19th, 2026 6:00 am
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Mar 17th, 2026 6:25 am
BC-Most Active Stocks - Mar 10th, 2026 8:30 am
BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 - Mar 5th, 2026 6:00 am
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy - Mar 4th, 2026 6:00 am
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs - Feb 24th, 2026 6:30 am
BioRestorative Announces Closing of $5.0 Million Public Offering - Feb 13th, 2026 6:30 pm
BioRestorative Announces Pricing of $5.0 Million Public Offering - Feb 11th, 2026 8:30 pm
BioRestorative Announces Positive Outcome from Type B Meeting with FDA - Feb 11th, 2026 5:30 am
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease - Feb 10th, 2026 6:00 am
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease - Nov 17th, 2025 5:00 am
BioRestorative (BRTX) Earnings Call Transcript - Nov 13th, 2025 10:04 am